Patient Square Capital’s Nektar Therapeutics NKTR Stock Holding History

Patient Square Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.1M	Buy	+210,000	New	+$12M	2.68%	9

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Patient Square Capital's NKTR Position: Q1 2026 in Review

Patient Square Capital opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 210,000 shares worth $15.1M. The stake represents 2.68% of the portfolio and ranks #9 among its holdings.

215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Patient Square Capital held 210,000 shares of Nektar Therapeutics worth $15.1M as of Q1 2026.
Nektar Therapeutics was a new Patient Square Capital position in Q1 2026.
Nektar Therapeutics made up 2.68% of Patient Square Capital's portfolio in Q1 2026, its #9 holding.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Patient Square Capital's 13F filing for Q1 2026, filed 15 May 2026.